EX-10.13



 Exhibit 10.13 

TOCAGEN INC. 
 EXECUTIVE
EMPLOYMENT AGREEMENT 
 This Executive Employment Agreement (the “Agreement”) is made and
entered into effective as of February 27, 2017 (the “Effective Date”), by and between Mark Foletta (“Executive”) and Tocagen Inc. (the “Company”). 

WHEREAS, the Company and Executive desire to enter into this Agreement to define their
mutual rights and duties with respect to Executive’s compensation and benefits. 
 NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree
as follows: 
 1.     Employment by the Company. 

1.1     Position. Executive shall serve as the Company’s Executive Vice President and Chief
Financial Officer (“CFO”). Executive’s start date will be February 27, 2017, or such other date as mutually agreed by Executive and the Company (the “Start Date”). During the term of
Executive’s employment with the Company, Executive will devote Executive’s best efforts and substantially all of Executive’s business time and attention to the business of the Company, except for approved vacation periods and
reasonable periods of illness or other incapacities permitted by the Company’s general employment policies. 

1.2     Duties and Location. Executive shall perform such duties as are customarily associated with
the position of CFO and such other duties as are assigned to Executive by the Company’s Chief Executive Officer. Executive’s primary office location shall be the Company’s headquarters located in San Diego, California. Subject to the
terms of this Agreement, the Company reserves the right to (a) reasonably require Executive to perform Executive’s duties at places other than Executive’s primary office location from time to time and to require reasonable business
travel, and (b) modify Executive’s job title and duties as it deems necessary and appropriate in light of the Company’s needs and interests from time to time. 

1.3     Policies and Procedures. The employment relationship between the parties shall be governed
by the general employment policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement shall control. 

2.     Cash Compensation. 

2.1     Base Salary. For services to be rendered hereunder, Executive shall receive a base salary
at the rate of $350,000 per year (the “Base Salary”), less standard payroll deductions and withholdings and payable in accordance with the Company’s regular payroll schedule. The Company’s Board of Directors (the
“Board”) may review Executive’s Base Salary for adjustment from time to time and it is expressly acknowledged and agreed that following the initial public offering of the Company’s common stock and listing of the
Company’s common stock on a national securities exchange (and regularly thereafter), the Board will review 

  
 1. 








 
Executive’s total compensation, including Base Salary, target and maximum bonus amounts and equity compensation, with the advice of an independent compensation consultant and publicly-traded
peer group company data. 
 2.2     Bonus. Executive will be eligible to be considered for a
discretionary annual performance bonus of up to 40% of the Base Salary, based on achievement of individual and/or corporate performance targets, metrics and/or objectives to be determined and approved by the Board or the Compensation Committee
thereof. Any such bonus would be paid after the close of the fiscal year and after determination by the Board (or the Compensation Committee thereof) of (i) the level of achievement of the applicable individual and corporate performance
targets, metrics and/or objectives and (ii) the amount of the annual incentive compensation earned by Executive (if any). No annual incentive compensation is guaranteed and, in addition to the other conditions for earning such compensation,
Executive must remain an employee in good standing of the Company on the annual incentive compensation payment date in order to be eligible for any annual incentive compensation. 

3.     Standard Company Benefits. Executive shall, in accordance with Company policy and the terms
and conditions of the applicable Company benefit plan documents, be eligible to participate in the benefit and fringe benefit programs provided by the Company to its executive officers and other employees from time to time. Any such benefits shall
be subject to the terms and conditions of the governing benefit plans and policies and may be changed by the Company in its discretion. 

4.     Other Expenses. The Company will reimburse Executive for reasonable travel, entertainment or
other expenses incurred by Executive in furtherance or in connection with the performance of Executive’s duties hereunder, in accordance with the Company’s expense reimbursement policy as in effect from time to time. 

5.     Equity Compensation. 

5.1     Base Options. As further consideration for Executive’s employment, promptly following
Executive’s Start Date and subject to approval by the Board, Executive will be granted a nonstatutory stock option (the “Base Option”) under the Company’s 2009 Equity Incentive Plan, as amended (the
“Plan”) to purchase up to 480,493 shares of the Company’s common stock. The Base Option will have an exercise price equal to the fair market value of the Common Stock as of the date of grant as determined by the Board
and shall vest as follows: (i) 25% of the shares subject to the Base Option shall vest twelve months after the Start Date, subject to Executive’s continuing employment with the Company, and no shares shall vest before such date. The
remaining shares shall vest monthly on the last day of the each of the following 36 months in equal monthly amounts subject to Executive’s continuing employment with the Company. The vesting of 100% of the Base Option shall be subject to full
acceleration such that, immediately prior the effective time of a Change in Control (defined in the Plan) such shares shall be fully vested and immediately exercisable. The terms of the Base Option are more fully set forth in the Plan and related
grant notice and stock option agreement (together, the “Equity Documents”). 

  
 2. 








 5.2     Performance Options. In addition, promptly
following the Start Date and subject to approval by the Board, Executive will be granted a nonstatutory stock option (the “Performance Option”) under the Plan to purchase up to an additional 236,661 shares of the
Company’s Common Stock. The Performance Option will have an exercise price equal to the fair market value of the Common Stock as of the date of grant as determined by the Board and shall vest upon the achievement of milestone(s) as more fully
set forth in the Equity Documents for the Performance Option. In the event of a Change in Control prior to the full vesting of the Performance Option, the Board shall have the discretion to accelerate vesting of the Performance Option, in whole or
in part, based on progress towards the milestones. The Equity Documents contain additional terms and conditions applicable to the Performance Option. 

6.     Proprietary Information Obligations. 

6.1     Proprietary Information Agreement. As a condition to employment, Executive agrees to
execute, and will continue to abide by, the Company’s standard Confidential Information and Invention Assignment Agreement attached hereto as EXHIBIT A (“Proprietary Agreement”). 

6.2     Third-Party Agreements and Information. Executive represents and warrants that
Executive’s employment by the Company does not conflict with any prior employment or consulting agreement or other agreement with any third party, and that Executive will perform Executive’s duties to the Company without violating any such
agreement. Executive represents and warrants that Executive does not possess confidential information arising out of prior employment, consulting, or other third party relationships, that would be used in connection with Executive’s employment
by the Company, except as expressly authorized by that third party. During Executive’s employment by the Company, Executive will use in the performance of Executive’s duties only information that is generally known and used by persons with
training and experience comparable to Executive’s own, common knowledge in the industry, otherwise legally in the public domain, or obtained or developed by the Company or by Executive in the course of Executive’s work for the Company.

 7.     Outside Activities and Non-Competition and No-Solicit. 

7.1     Outside Activities. Throughout Executive’s employment with the Company, Executive may
engage in civic and not-for-profit activities so long as such activities do not interfere with the performance of Executive’s duties hereunder or present a conflict of interest with the Company or its affiliates. Subject to the restrictions set
forth herein, and only with prior written disclosure to and consent of the Board, Executive may engage in other types of business or public activities (and, for the avoidance of doubt, the activities listed on ANNEX I attached
hereto are deemed disclosed to, and consented by, the Board). The Board may rescind such consent, if the Board determines, in its sole discretion, that such activities compromise or threaten to compromise the Company’s or its affiliates’
business interests or conflict with Executive’s duties to the Company or its affiliates. 

7.2     Non-Competition During Employment. Except as otherwise provided in this Agreement, during
Executive’s employment by the Company, Executive will not, without the express written consent of the Board, directly or indirectly serve as an officer, director, 

  
 3. 








 
stockholder, employee, partner, proprietor, investor, joint venturer, associate, representative or consultant of any person or entity engaged in, or planning or preparing to engage in, business
activity competitive with any line of business engaged in (or planned to be engaged in) by the Company or its affiliates; provided, however, that Executive may purchase or otherwise acquire up to (but not more than) one percent (1%) of any
class of securities of any enterprise (without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. In addition, Executive will be subject to certain restrictions
(including restrictions continuing after Executive’s employment ends) under the terms of the Proprietary Agreement. 

7.3     Non-Solicitation. Executive agrees that during the period of employment with the Company
and for twelve (12) months after the date Executive’s employment is terminated for any reason, Executive will not, either directly or through others, solicit or encourage or attempt to solicit or encourage any employee, independent
contractor, or consultant of the Company to terminate his or her relationship with the Company in order to become an employee, consultant or independent contractor to or for any other person or entity. 

8.     Termination of Employment. 

8.1     At-Will Employment. Executive’s employment relationship is at-will. Either Executive
or the Company may terminate the employment relationship at any time, with or without Cause (as defined below) or advance notice. In the event Executive’s employment with the Company is terminated for any reason, Executive will be entitled to
all of Executive’s earned compensation and benefits or otherwise as required by law through the date of termination. For the avoidance of doubt, Executive shall not be entitled to any additional compensation or benefits hereunder in the event
Executive’s employment is terminated for Cause, due to Executive’s resignation without Good Reason, upon Executive’s death or Executive’s Disability (as defined below); provided that this Section 8.1 does not purport
to alter (a) any separate agreement entered into after the Effective Date and pursuant which Executive is expressly entitled to benefits or other compensation on or after the events set forth in this sentence, including, if applicable, the
Equity Documents, or (b) any agreements between the Executive and any third party, including insurance policies or the like. If Executive’s employment terminates due to an Involuntary Termination (as defined below), Executive will be
eligible to receive the additional compensation and benefits described in Section 8.2. 

8.2     Termination Without Cause; Resignation for Good Reason. If at any time (i) the Company
terminates Executive’s employment without Cause (as defined below and other than as a result of Executive’s death or Disability), or (ii) Executive resigns for Good Reason (as defined below), and provided in any case such termination
constitutes a “separation from service”, as defined under Treasury Regulation Section 1.409A-1(h)) (a “Separation from Service”) (such termination described in (i) or (ii), an “Involuntary
Termination”), Executive shall be entitled to receive the following severance benefits, subject in all events to Executive’s compliance with Section 8.4 below: 

(i)     Executive shall receive severance pay in the form of continuation of Executive’s base
salary in effect (ignoring any decrease that forms the basis for Executive’s resignation for Good Reason, if applicable) on the effective date of Executive’s Involuntary 

  
 4. 








 
Termination for the first twelve (12) months (the “Severance Period”) after the date of such termination; 

(ii)     If Executive is eligible for and timely elects to continue Executive’s health
insurance coverage under the Company’s group health plans under the Consolidated Omnibus Budget Reconciliation Act of 1985 or the state equivalent (“COBRA”) following Executive’s termination date, the Company will
pay the COBRA group health insurance premiums for Executive and Executive’s eligible dependents until the earliest of (A) the close of the Severance Period, (B) the expiration of Executive’s eligibility for the continuation
coverage under COBRA, or (C) the date when Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment. For purposes of this Section, references to COBRA premiums shall
not include any amounts payable by Executive under a Section 125 health care reimbursement plan under the U.S. Internal Revenue Code. Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it cannot
pay the COBRA premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then regardless of whether Executive elects continued health
coverage under COBRA, and in lieu of providing the COBRA premiums, the Company will instead pay Executive on the last day of each remaining month of the Severance Period, a fully taxable cash payment equal to the COBRA premiums for that month,
subject to applicable tax withholdings (such amount, the “Health Care Benefit Payment”). The Health Care Benefit Payment shall be paid in monthly installments on the same schedule that the COBRA premiums would otherwise have
been paid and shall be equal to the amount that the Company would have otherwise paid for COBRA premiums, and shall be paid until the earlier of (i) expiration of the Severance Period or (ii) the date when Executive becomes eligible for
substantially equivalent health insurance coverage in connection with new employment or self-employment; and 

(iii)     Executive shall receive an extension of the period of time following which Executive may
exercise vested shares subject to Executive’s equity awards to purchase Company common stock that are outstanding immediately prior to Executive’s Involuntary Termination until the date that is the earlier of (i) the original
Expiration Date (as defined in the respective Equity Documents for such options) and (ii) twelve (12) months following the date of Involuntary Termination; provided, however, that Executive’s rights to exercise vested options may
terminate prior to such date, in accordance with the terms of the equity plan under which such options were granted (including upon a corporate transaction) or Executive’s violation of the Proprietary Agreement or the Release (defined
below).
 8.3     Conditions and Timing for Severance Benefits. The severance benefits set forth
in Section 8.2 above are expressly conditioned upon: (i) Executive’s continuing to comply with Executive’s obligations under Executive’s Proprietary Agreement; and (ii) Executive signing and not revoking a general
release of legal claims in the form provided by the Company which shall include a full general release of claims against the Company and related persons and entities and a commitment from Executive to comply with Executive’s continuing
obligations under Executive’s Proprietary Agreement, but will not include a release of any rights or claims for indemnification Executive may have pursuant to any written indemnification agreement with the Company to which Executive is a party,
the Company’s bylaws, or applicable law (the “Release”) within the applicable deadline set forth therein and permitting the 

  
 5. 








 
Release to become effective in accordance with its terms, which must occur no later than forty-five (45) days following the date of termination (the “Release
Deadline”). The salary continuation payments described in Section 8.2 will be paid in substantially equal installments on the Company’s regular payroll schedule and subject to standard deductions and withholdings over the
Severance Period following termination; provided, however, that no payments will be made prior to the effectiveness of the Release. On the effective date of the Release, the Company will pay Executive the salary continuation payments that Executive
would have received on or prior to such date in a lump sum under the original schedule but for the delay while waiting for the effectiveness of the release, with the balance of the cash severance being paid as originally scheduled. 

8.4     Definitions. For purposes of this Agreement: 

(i)     “Cause” means, with respect to Executive, the occurrence of any of
the following events: (i) Executive’s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) Executive’s attempted commission of, or
participation in, a fraud or act of dishonesty against the Company; (iii) Executive’s intentional, material violation of any contract or agreement between Executive and the Company or of any statutory duty owed to the Company that has not
been cured, if curable, within fifteen (15) days after written notice from the Board of such violation; (iv) Executive’s unauthorized use or disclosure of the Company’s confidential information or trade secrets; or
(v) Executive’s gross misconduct that has not been cured, if curable, within fifteen (15) days after written notice from the Board requesting that the Executive cure such misconduct. 

(ii)     “Disability” means the inability of a Executive to engage in
substantially gainful Company activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than twelve
(12) months, and shall be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. 

(iii)     “Good Reason” means Executive’s resignation from employment
with the Company (or successor to the Company, if applicable) due to any of the following actions taken by the Company (or successor to the Company, if applicable) without Executive’s prior written consent thereto: (1) a material reduction
in Executive’s base salary, which the parties agree is a reduction of at least 10% of Executive’s base salary (unless pursuant to a salary reduction program applicable generally to the Company’s similarly situated employees);
(2) a material reduction in Executive’s authority, duties or responsibilities; (3) a material reduction in the authority, duties, or responsibilities of the supervisor to whom Executive is required to report, including a requirement
that Executive reports to a corporate officer or employee instead of reporting directly to the Chief Executive Officer; (4) a relocation of Executive’s principal place of employment to a place that increases Executive’s one-way
commute by more than fifty (50) miles as compared to Executive’s then-current principal place of employment immediately prior to such relocation (excluding regular travel in the ordinary course of business); and (5) a breach of a
material provision of this Agreement by the Company. Notwithstanding the foregoing, in order to resign for Good Reason, Executive must provide written notice to the 

  
 6. 








 
Company within thirty (30) days after the first occurrence of the event giving rise to Good Reason setting forth the basis for Executive’s resignation and allow the Company at least
thirty (30) days from receipt of such written notice to cure such event, and, if such event is not reasonably cured within such period, Executive’s resignation from all positions Executive then holds with the Company is effective not later
than thirty (30) days after the expiration of the cure period. 
 8.5     Section 409A.
It is intended that all of the benefits and other payments payable under this Agreement satisfy, to the greatest extent possible, an exemption from the application of Section 409A of the Internal Revenue Code of 1986, as amended (the
“Code”) and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”), and this Agreement will be construed to the greatest extent
possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A, and any ambiguities herein shall be interpreted
accordingly. Specifically, the benefits under this Agreement are intended to satisfy the exemptions from application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9) and each
installment of severance benefits is a separate “payment” for purposes of Treasury Regulations Section 1.409A-2(b)(2)(i). However, if such exemptions are not available and Executive is, upon Separation from Service, a “specified
employee” for purposes of Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences under Section 409A, the timing of the severance benefits payments shall be delayed until the earlier of
(i) six (6) months and one day after Executive’s Separation from Service, or (ii) Executive’s death. Severance benefits shall not commence until Executive has a Separation from Service. If the severance benefits are not
covered by one or more exemptions from the application of Section 409A and the Release could become effective in the calendar year following the calendar year in which Executive’s Separation from Service occurs, the Release will not be
deemed effective, for purposes of payment of severance, any earlier than the Release Deadline. Except to the minimum extent that payments must be delayed because Executive is a “specified employee” or until the effectiveness of the
Release, all severance amounts will be paid as soon as practicable in accordance with the Company’s normal payroll practices. 

8.6     Section 280G. If any payment or benefit Executive will or may receive from the Company
or otherwise (a “Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by
Section 4999 of the Code (the “Excise Tax”), then such Payment will be equal to the Reduced Amount (defined below). The “Reduced Amount” will be either (l) the largest portion of the Payment
that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (2) the entire Payment, whichever amount after taking into account all applicable federal, state and local employment taxes, income taxes, and
the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in Executive’s receipt, on an after-tax
basis, of the greatest amount of the Payment. If a reduction in the Payment is to be made so that the Payment equals the Reduced Amount, (x) the Payment will be paid only to the extent permitted under the Reduced Amount alternative, and the
Executive will have no rights to any additional payments and/or benefits constituting the Payment, and (y) reduction in payments and/or benefits will occur in the following order: (1)

  
 7. 








 
reduction of cash payments; (2) cancellation of accelerated vesting of equity awards other than stock options; (3) cancellation of accelerated vesting of stock options; and
(4) reduction of other benefits paid to Executive. In the event that acceleration of vesting of equity award compensation is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant of
Executive’s equity awards. In no event will the Company or any stockholder be liable to Executive for any amounts not paid as a result of the operation of this Section. The professional firm engaged by the Company for general tax purposes as of
the day prior to the effective date of the change in control will perform the foregoing calculations. If the tax firm so engaged by the Company is serving as accountant or auditor for the acquirer, the Company will appoint a nationally recognized
tax firm to make the determinations required hereunder. The Company will bear all expenses with respect to the determinations by such firm required to be made hereunder. If the tax firm determines that no Excise Tax is payable with respect to a
Payment, either before or after the application of the Reduced Amount, it will furnish the Company and Executive with documentation that no Excise Tax is reasonably likely to be imposed with respect to such Payment. Any good faith determinations of
the tax firm made hereunder will be final, binding and conclusive upon the Company and Executive. 

9.     Dispute Resolution. To ensure the rapid and economical resolution of disputes that may arise
in connection with Executive’s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the
enforcement, breach, performance, or interpretation of this Agreement, Executive’s employment with the Company, or the termination of Executive’s employment from the Company, will be resolved pursuant to the Federal Arbitration Act, 9
U.S.C. §1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted in San Diego, California by JAMS, Inc. (“JAMS”) or its successors, under JAMS’ then applicable rules
and procedures for employment disputes (which can be found at http://www.jamsadr.com/rules-clauses/, and which will be provided to Executive on request); provided that the arbitrator shall: (a) have the authority to compel adequate discovery
for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written arbitration decision including the arbitrator’s essential findings and conclusions and a statement of the award.
Executive and the Company shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law. Both Executive and the Company acknowledge that by agreeing to this arbitration procedure, they waive the right to
resolve any such dispute through a trial by jury or judge or administrative proceeding. The Company shall pay all filing fees in excess of those which would be required if the dispute were decided in a court of law, and shall pay the
arbitrator’s fee. Nothing in this Agreement is intended to prevent either the Company or Executive from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. 

10.     General Provisions. 

10.1     Notices. Any notices provided must be in writing and will be deemed effective upon the
earlier of personal delivery (including personal delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll. 

  
 8. 








 10.2     Severability. Whenever possible, each
provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule
in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping
with the intent of the Parties. 
 10.3     Waiver. Any waiver of any breach of any provisions of
this Agreement must be in writing to be effective, and it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. 

10.4     Complete Agreement. This Agreement, together with the Proprietary Agreement, and the
Indemnification Agreement attached hereto as EXHIBIT B, constitutes the entire agreement between Executive and the Company with regard to the subject matter hereof and is the complete, final, and exclusive embodiment of the
Company’s and Executive’s agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any
other such promises, warranties or representations. It cannot be modified or amended except in a writing signed by a duly authorized officer of the Company, with the exception of those changes expressly reserved to the Company’s discretion in
this Agreement. 
 10.5     Counterparts. This Agreement may be executed in separate
counterparts, any one of which need not contain signatures of more than one party, but both of which taken together will constitute one and the same Agreement. 

10.6     Headings. The headings of the paragraphs hereof are inserted for convenience only and
shall not be deemed to constitute a part hereof nor to affect the meaning thereof. 
 10.7
    Successors and Assigns. This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except
that Executive may not assign any of Executive’s duties hereunder and Executive may not assign any of Executive’s rights hereunder without the written consent of the Company, which shall not be withheld unreasonably. 

10.8     Tax Withholding. All payments and awards contemplated or made pursuant to this Agreement
will be subject to withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company has neither made any assurances nor any guarantees
concerning the tax treatment of any payments or awards contemplated by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the tax and economic consequences of all
payments and awards made pursuant to the Agreement. 
 10.9     Choice of Law. All questions
concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of California. 

  
 9. 








 [Signature Page Follows] 

  
 10. 








 IN WITNESS WHEREOF, the parties have executed
this Agreement on the date first written above. 
  

			
	TOCAGEN INC.
		
	 By:
	 	 /s/ Marty Duvall

		 	Marty Duvall
		 	Chief Executive Officer
	
	 EXECUTIVE

	
	 /s/ Mark Foletta

	 MARK FOLETTA




  
 11. 








 ANNEX I 

Member of the board of directors of Dexcom, and any committees thereof. 

Member of board of directors of Regulus Therapeutics, and any committees thereof. 

Member of the board of directors of AMN Healthcare, and any committees thereof. 

Member of the board of directors of ViaCyte, and any committees thereof. 

  
 12. 








 EXHIBIT A 

PROPRIETARY AGREEMENT 

  
 13. 








 EXHIBIT B 

INDEMNIFICATION AGREEMENT 

  
 14.